Aquestive Therapeutics (NASDAQ:AQST) Now Covered by Cantor Fitzgerald

Cantor Fitzgerald assumed coverage on shares of Aquestive Therapeutics (NASDAQ:AQST) in a research report sent to investors on Tuesday, Marketbeat Ratings reports. The brokerage issued an overweight rating and a $17.00 target price on the stock.

Other equities analysts have also issued research reports about the stock. JMP Securities reissued a “market outperform” rating and issued a $9.00 price objective on shares of Aquestive Therapeutics in a research report on Tuesday, October 8th. Leerink Partners boosted their price target on Aquestive Therapeutics from $12.00 to $13.00 and gave the company an “outperform” rating in a report on Friday, October 25th. Finally, HC Wainwright reissued a “buy” rating and set a $10.00 price target on shares of Aquestive Therapeutics in a research note on Wednesday, November 6th. Six analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, Aquestive Therapeutics currently has an average rating of “Buy” and an average price target of $11.00.

Aquestive Therapeutics Stock Performance

Aquestive Therapeutics stock opened at $3.85 on Tuesday. Aquestive Therapeutics has a fifty-two week low of $1.84 and a fifty-two week high of $6.23. The company has a market capitalization of $351.04 million, a price-to-earnings ratio of -8.56 and a beta of 2.62. The stock has a fifty day moving average of $4.81 and a two-hundred day moving average of $4.06.

Aquestive Therapeutics (NASDAQ:AQST) last posted its quarterly earnings data on Monday, November 4th. The company reported ($0.13) EPS for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.01). The company had revenue of $13.54 million during the quarter, compared to analysts’ expectations of $12.69 million. During the same period in the previous year, the company posted ($0.03) EPS. On average, analysts forecast that Aquestive Therapeutics will post -0.47 EPS for the current fiscal year.

Hedge Funds Weigh In On Aquestive Therapeutics

A number of hedge funds have recently made changes to their positions in the stock. Victory Capital Management Inc. purchased a new position in shares of Aquestive Therapeutics in the 2nd quarter worth $27,000. nVerses Capital LLC purchased a new position in shares of Aquestive Therapeutics in the 3rd quarter worth about $28,000. The Manufacturers Life Insurance Company acquired a new position in shares of Aquestive Therapeutics in the 2nd quarter valued at about $76,000. Financial Advocates Investment Management grew its holdings in shares of Aquestive Therapeutics by 70.0% during the 2nd quarter. Financial Advocates Investment Management now owns 34,000 shares of the company’s stock worth $88,000 after purchasing an additional 14,000 shares during the period. Finally, Harvey Capital Management Inc. acquired a new stake in Aquestive Therapeutics during the 3rd quarter worth approximately $88,000. Institutional investors and hedge funds own 32.45% of the company’s stock.

About Aquestive Therapeutics

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.